A National Report from China Liver Transplant Registry: Steroid Avoidance After Liver Transplantation for Hepatocellular Carcinoma

Overview

Journal Chin J Cancer Res

Specialty Oncology

Date 2017 Nov 17

PMID 29142462

Citations 5

Authors

Qiang Wei

Feng Gao

Runzhou Zhuang

Qi Ling

Qinghong Ke

Jian Wu

Tian Shen

Mangli Zhang

Min Zhang

Xiao Xu

Shusen Zheng

Affiliations

Soon will be listed here.

Abstract

Objective: We aimed to evaluate the efficacy and safety of steroid-free immunosuppression after liver transplantation (LT) for hepatocellular carcinoma (HCC).

Methods: We retrospectively analyzed HCC recipients without steroids after LT (SF group, n=368) based on the China Liver Transplant Registry (CLTR) database. These recipients were matched 1:2 with patients using steroids (S group, n=736) for the same period after LT for HCC, according to propensity scores.

Results: Multivariate analysis indicates that recipients with younger age [odds ratio (OR), 1.053; P=0.011], preoperative hepatitis B virus (HBV) DNA ≥1,000 copies/mL (OR, 2.597; P=0.004) and beyond Milan criteria (OR, 4.255; P<0.001) were identified as the risk factors associated with tumor recurrence in steroid avoidance recipients after LT. The patients fulfilling the Milan criteria in the SF group presented higher overall and tumor-free survival rates than those in the S group (P<0.05). Multivariate analysis revealed that recipient beyond Milan criteria was an independent prognostic factor for overall survival (OR, 1.690; P<0.001) and tumor-free survival (OR, 2.066; P<0.001). The incidences of new-onset diabetes mellitus (21.20%. 33.29%, P<0.001), new-onset hypertension (10.05%. 18.61%, P<0.001) and hyperlipidemia (4.08%. 7.20%, P=0.042) were significantly lower in the SF group.

Conclusions: Steroid-free immunosuppression could be safe and feasible for HBV-related HCC patients in LT. Age, HBV DNA level and Milan criteria maybe risk factors associated with tumor recurrence in steroid avoidance recipients. Recipient beyond Milan criteria was an independent prognostic factor and recipient fulfilling Milan criteria can benefit the most from steroid-free immunosuppression.

Citing Articles

Serum resistin and the risk for hepatocellular carcinoma in diabetic patients.

Abdalla M World J Gastroenterol. 2023; 29(27):4271-4288.

PMID: 37545641 PMC: 10401662. DOI: 10.3748/wjg.v29.i27.4271.

Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?.

Jiang J, Huang H, Chen R, Lin Y, Ling Q Front Immunol. 2023; 14:1092401.

PMID: 36875077 PMC: 9978931. DOI: 10.3389/fimmu.2023.1092401.

Efficacy and safety of lenvatinib for preventing tumor recurrence after liver transplantation in hepatocellular carcinoma beyond the Milan criteria.

Guo D, Cheng J, Yan J, Huang A, Wang Y, Zhang S Ann Transl Med. 2022; 10(20):1091.

PMID: 36388794 PMC: 9652551. DOI: 10.21037/atm-22-1353.

The Korean Organ Transplantation Registry (KOTRY): an overview and summary of the kidney-transplant cohort.

Jeon H, Koo T, Ju M, Chae D, Choi S, Kim M Kidney Res Clin Pract. 2022; 41(4):492-507.

PMID: 35919926 PMC: 9346403. DOI: 10.23876/j.krcp.21.185.

Expert consensus on management of metabolic disease in Chinese liver transplant recipients.

Shen T, Zhuang L, Sun X, Qi X, Wang Z, Li R World J Gastroenterol. 2020; 26(27):3851-3864.

PMID: 32774062 PMC: 7385566. DOI: 10.3748/wjg.v26.i27.3851.

References

Zhou L, Rui J, Wang S, Chen S, Qu Q . Early recurrence in large hepatocellular carcinoma after curative hepatic resection: prognostic significance and risk factors. Hepatogastroenterology. 2015; 61(135):2035-41. View

Taylor A, Watson C, Bradley J . Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005; 56(1):23-46. DOI: 10.1016/j.critrevonc.2005.03.012. View

Ma X, Yang Y, Tu H, Gao J, Tan Y, Zheng J . Risk prediction models for hepatocellular carcinoma in different populations. Chin J Cancer Res. 2016; 28(2):150-60. PMC: 4865607. DOI: 10.21147/j.issn.1000-9604.2016.02.02. View

Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y . Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl. 2006; 12(2):253-8. DOI: 10.1002/lt.20701. View

Stegall M, Everson G, SCHROTER G, Karrer F, Bilir B, Sternberg T . Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. Hepatology. 1997; 25(1):173-7. DOI: 10.1002/hep.510250132. View

Liu Y, Li C, Huai M, Fu X, Cui Z, Fan L . Comprehensive comparison of three different immunosuppressive regimens for liver transplant patients with hepatocellular carcinoma: steroid-free immunosuppression, induction immunosuppression and standard immunosuppression. PLoS One. 2015; 10(3):e0120939. PMC: 4376790. DOI: 10.1371/journal.pone.0120939. View

Gundisch S, Boeckeler E, Behrends U, Amtmann E, Ehrhardt H, Jeremias I . Glucocorticoids augment survival and proliferation of tumor cells. Anticancer Res. 2012; 32(10):4251-61. View

Chuma M, Hige S, Kamiyama T, Meguro T, Nagasaka A, Nakanishi K . The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2009; 44(9):991-9. DOI: 10.1007/s00535-009-0093-z. View

Ling Q, Xie H, Lu D, Wei X, Gao F, Zhou L . Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population. J Hepatol. 2012; 58(2):271-7. DOI: 10.1016/j.jhep.2012.09.025. View

10.

Yang P, Ho C, Hu R, Ho M, Wu Y, Lee P . Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma. World J Hepatol. 2016; 8(31):1309-1317. PMC: 5099583. DOI: 10.4254/wjh.v8.i31.1309. View

11.

Calmus Y, Scheele J, Gonzalez-Pinto I, Jaurrieta E, Klar E, Pageaux G . Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl. 2002; 8(2):123-31. DOI: 10.1053/jlts.2002.30882. View

12.

Hu A, Wu L, Tai Q, Zhu X, He X . Safety and efficacy of four steroid-minimization protocols in liver transplant recipients: 3-year follow-up in a single center. J Dig Dis. 2012; 14(1):38-44. DOI: 10.1111/1751-2980.12008. View

13.

Zaydfudim V, Pelletier S . Towards Steroid-Free Immunosuppression after Liver Transplantation. Gut Liver. 2016; 10(4):495-6. PMC: 4933405. DOI: 10.5009/gnl16204. View

14.

Senkerikova R, Frankova S, Sperl J, Oliverius M, Kieslichova E, Filipova H . Incidental hepatocellular carcinoma: risk factors and long-term outcome after liver transplantation. Transplant Proc. 2014; 46(5):1426-9. DOI: 10.1016/j.transproceed.2014.03.010. View

15.

Yang T, Lu J, Zhai J, Lin C, Yang G, Zhao R . High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol. 2012; 38(8):683-91. DOI: 10.1016/j.ejso.2012.04.010. View

16.

Gruttadauria S, Cintorino D, Piazza T, Mandala L, Doffria E, Musumeci A . A safe immunosuppressive protocol in adult-to-adult living related liver transplantation. Transplant Proc. 2006; 38(4):1106-8. DOI: 10.1016/j.transproceed.2006.02.141. View

17.

Kim J, Joh J, Kim S, Kwon C, Song S, Shin M . Steroid withdrawal in adult liver transplantation: occurrence at a single center. Transplant Proc. 2010; 42(10):4132-6. DOI: 10.1016/j.transproceed.2010.10.018. View

18.

Linden A . A comparison of approaches for stratifying on the propensity score to reduce bias. J Eval Clin Pract. 2017; 23(4):690-696. DOI: 10.1111/jep.12701. View

19.

Shigeta T, Sakamoto S, Uchida H, Sasaki K, Hamano I, Kanazawa H . Basiliximab treatment for steroid-resistant rejection in pediatric patients following liver transplantation for acute liver failure. Pediatr Transplant. 2014; 18(8):860-7. DOI: 10.1111/petr.12373. View

20.

Sen S, Dawwas M, Nash K, Gimson A . Uncomplicated strongyloidiasis in a liver transplant recipient on steroid-free immunosuppression. Transpl Infect Dis. 2010; 12(2):184-5. DOI: 10.1111/j.1399-3062.2009.00462.x. View